Proportion of participants who withdrew due to adverse events between 0 and 14 weeks · predominantly knee osteoarthritis
Antidepressant probably leads to higher proportion of participants who withdrew due to adverse events… compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher reduction of inflammation: proportion with 50% or greater decrease… compared with placebo (low certainty).
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
Low‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
Low‐dose colchicine showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher participant global assessment of treatment success: proportion with… compared with placebo (low certainty).
1 finding from 1 review
Proportion with complete resolution of a target tophus · participants with tophi in gout
Pegloticase every two weeks (biweekly) probably leads to higher proportion with complete resolution of tophi compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
Serum urate normalisation ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review